7 STRAITS VIEW, SINGAPORE, U0
Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces Hearing on Proposed Redomiciliation to the United States
Announces Proposed Redomiciliation to the United States
Wave Life Sciences Reports Positive Phase 1 INLIGHT Data: Body Composition and Fat Reductions
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Investor Presentation
Q1
FY 2024
Q3
Q2
Amended Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
PRER14A
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement